Autoantibodies to p53 in sera of patients with autoimmune thyroid disease

Annals of Clinical and Laboratory Science

Volumn 30, Issue 2, 2000, Pages 179-184

  Fenton, Cydney L ^a,b   Patel, Aneeta ^a   Tuttle, R Michael ^a   Francis, Gary L ^a,b  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

Autoimmunity; p53; Thyroid; Tumor suppressor gene

Indexed keywords

AUTOANTIBODY; PROTEIN P53;

ADOLESCENT; ADULT; AGED; ANTIBODY DETECTION; CHILD; FEMALE; GRAVES DISEASE; HASHIMOTO DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSEUDOHYPOPARATHYROIDISM; REVIEW; THYROID CANCER;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; CHILD; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOBLOTTING; MALE; MIDDLE AGED; THYROID NEOPLASMS; THYROIDITIS, AUTOIMMUNE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034102375     PISSN: 00917370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (14)

1. Marxen J, Schmiegel W, Röder C, Harder R, Juhl H, Henne-Bruns D, Kremer B, Kalthoff H. Detection of the anti-p53 antibody response in malignant and benign pancreatic disease. Br J Cancer 1994;70:1031-1034.
2. Ryder SD, Rizzi PM, Volkmann M, Metivier E, Pereira L, Galle PR, Naoumov NV, Zentgraf H, Williams R. Use of specific ELISA for the detection of antibodies directed against p53 protein in patients with hepatocellular carcinoma. J Clin Pathol 1996;49:295-299.
3. Lubin R, Schlichtholz B, Teillaud JL, Garay E, Bussel A, Wild CP, Soussi T. p53 Antibodies in patients with various types of cancer: assay, identification, and characterization. Clin Cancer Res 1995;1:1463-1469.
4. Soussi T. The humoral response to the tumor-suppressor gene-product p53 in human cancer: implications for diagnosis and therapy. Immunol Today 1996;8:354-356.
5. Schlichtholz B, Legros Y, Gillet D, Gaillard C, Marty M, Lane D, Calvo F, Soussi T. The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res 1992;52:6380-6384.
6. Volkmann M, Müller M, Hofmann WJ, Meyer M, Hagelstein J, Räth U, Kommerell B, Zentgraf H, Galle PR. The humoral immune response to p53 in patients with hepatocellular carcinoma is specific for malignancy and independent of the α-fetoprotein status. Hepatology 1993; 18:559-565.
7. Benchimol S, Pim D, Crawford L. Radioimmunoassay of the cellular protein p53 in mouse and human cell lines. EMBO 1982; 1:1055-1062.
8. Kovacs B, Patel A, Hershey J, Dennis GJ, Kirschfink M. Antibodies against p53 in sera from patients with systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum 1997;40:980-985.
9. WAF1 expression in lymphocytic thyroiditis and thyroid tumors. Clin Immunol Immunopathol 1998;88:183-199.
10. Chetty R, O'Leary JJ, Biddolph SC, Gatter KC. Immunohistochemical detection of p53 and Bcl-2 proteins in Hashimoto's thyroiditis and primary thyroid lymphomas. J Clin Pathol 1995; 48:239-241.
11. Dobashi Y, Sakamoto A, Sugimura H, Mernyei M, Mori M, Oyama T, Machinami R. Overexpression of p53 as a possible prognostic factor in human thyroid carcinoma. Am J Surg Pathol 1993;17:375-381.
12. Ito T, Seyama T, Mizuno T, Tsuyama N, Hayashi T, Hayashi Y, Dohi K, Makamura N, Akiyama M. Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res 1992;52:1369-1371.
13. Ito T, Seyama T, Mizuno T, Tsuyama N, Hayashi Y, Dohi K, Makamura N, Akiyama M. Genetic alterations in thyroid tumor progression: association with p53 gene mutations. Jpn J Cancer Res 1993;84:526-531.
14. Mountz JD, Wu J, Cheng J, Zhou T. Autoimmune disease: a problem of defective apoptosis. Arthritis Rheum 1994;37:1415-1420.